Related Experiment Videos
Rhabdomyolysis during therapy with daptomycin.
Stella Papadopoulos1, Amanda M Ball, Susanne E Liewer
1Department of Pharmacy, University of Kentucky Chandler Medical Center, Lexington, Kentucky 40536, USA. spapa2@email.uky.edu
Summary
Daptomycin use can elevate creatine phosphokinase levels. This report details the first known case of rhabdomyolysis in a patient treated with daptomycin, a severe muscle condition.
Area of Science:
- Pharmacology
- Toxicology
- Infectious Diseases
Background:
- Daptomycin is an antibiotic used for serious Gram-positive bacterial infections.
- Elevated creatine phosphokinase (CPK) and myopathy are known risks associated with daptomycin therapy.
- Previous literature has not documented rhabdomyolysis in relation to daptomycin use.
Observation:
- A patient undergoing daptomycin treatment developed severe muscle symptoms.
- Clinical and laboratory findings were consistent with rhabdomyolysis.
Findings:
- This case represents the first documented instance of rhabdomyolysis in a patient receiving daptomycin.
- The patient's condition highlights a potential severe adverse effect of this antibiotic.
Implications:
- Clinicians should be vigilant for signs of rhabdomyolysis in patients treated with daptomycin.
- Further investigation into the mechanism of daptomycin-induced muscle injury is warranted.
- This finding may influence clinical guidelines for daptomycin use and patient monitoring.